There is a review of New Methods and Guidelines and Economists Network International (GENI), involving GENI Board members from America, UK, Australia, Canada and Denmark will discuss new methdologies and economic guidelines or 'checklists' for incorporating economic evidence into CPGs, […]
Latest Stories
Publish your research on preference measurement research now!
An invitation to submit to the next volume of Advances in Health Economics and Health Services Research entitled ‘Preference Measurement in Health’, edited by Glenn C Blomquist and Kristian Bolin. Submissions must be done by June 15, 2013 and emailed to: Glenn […]
Patient educational material too complex for average consumers
A new study, published Monday in JAMA Internal Medicine, suggests that despite good intentions many patient educational materials are too difficult for patients and their families to grasp. Content should draw people into your website and keep them engaged and digital marketers need to focus […]
On a quest for price transparency, drop confidentiality clauses!
Dina Overland, Editor of FierceHealthPayer, praises Rhode Island Insurance Commissioner Chris Koller's recent bulletin that requires health insurers to disclose coverage costs to providers and consumers upon request. She hopes that insurers in other states follow in Rhode […]
Pharma Must “Change Dialogue” around BRIC Markets
Pharma companies looking to expand into emerging markets such as Brazil, Russia, India and China (BRIC) must avoid cutting corners and concentrate more on establishing value according to a new report. Read more here. (Source: eyeforpharma, May 24, 2013) […]
False World Vs. Real World: A Strong Argument for RWD
Lucy Brake speaks to Mike Rea, CEO of IDEA Pharma, about how he believes real world evidence impacts current development and trials processes, and the ways in which pharma can take best take advantage of all this offers. Read entire article here. (Source: eyeforpharma, May 16, 2013) […]
In Search of the Silver Bullet: The Illusion of Big Data
This month Rita Numerof, Ph.D looks at the shortcomings of big data, suggesting that far from being an all-encompassing cure, it’s simply one of many solutions to pharma’s growth problems. Her conclusion? Dr. Numerof says, "Big data’s key shortcoming is this: while […]
Payers’ Use Of Real-World Evidence For Drug Coverage On The Rise
A new study by IMS Health shows payers globally are making more drug reimbursement decisions based on real-world evidence – including 25% of more than 100 identified case studies using biopharma industry-generated data. Paid access required to view entire article here. (Source: […]
What do you want to know about patient reported outcomes and experience measures?
Over the past year DHP Research has been posting a number of educational presentations on Slideshare. Click here to view the presentations which cover a range of issues including tips on selecting patient reported outcome and patient experience measures and questionnaire design. Rise of […]
The Oregon Experiment Revisited
Dr. Ashish Jha, revisits "The Oregon Experiment — Effects of Medicaid on Clinical Outcomes" by examining what worked in Oregon and what the report exposed - health insurance is a small part of a much bigger story about health in general, one that should not be ignored. […]
